Systemic inflammatory biomarkers as prognostic tools in patients with gastroesophageal adenocarcinoma.
Gastric cancer
Inflammation
Oesophageal cancer
Prognosis
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
22
08
2023
accepted:
12
09
2023
medline:
20
11
2023
pubmed:
26
9
2023
entrez:
26
9
2023
Statut:
ppublish
Résumé
Gastroesophageal adenocarcinoma is associated with poor prognosis, even in resectable stages. Systemic inflammation plays a key role in cancer progression. Yet, information on prognostic values of systemic inflammatory parameters in European cohorts is scarce. We analysed systemic inflammatory biomarkers (neutrophil-to-lymphocyte ratio (NLR), leucocyte-to-lymphocyte ratio (LLR), platelet-to-lymphocyte ratio (PLR), systemic inflammation response index (SIRI) and modified Glasgow Prognostic Score (mGPS)) at the time of cancer diagnosis and their association with overall survival (OS) in patients with gastroesophageal adenocarcinoma treated at the Medical University of Vienna between 1990 and 2020. In this analysis of 769 patients with gastroesophageal adenocarcinoma, higher mGPS (0-2) scores were associated with shorter OS in the overall cohort (24.9 versus 11.9 versus 7.6 months; HR 1.74, 95% CI 1.549-1.056; p < 0.001), in locally advanced (31.1 versus 19.8 versus 13.9 months, HR 1.561, 95% CI 1.274-1.912; p < 0.001) and in advanced/metastatic settings (12.3 versus 7.3 versus 5.8 months; HR 1.377, 95% CI 1.777-1.611; p < 0.001). In multivariate analyses, the association of mGPS with the OS stayed statistically significant in the locally advanced cohort (HR 1.397, 95% CI 1.068-1.828; p = 0.015), whereas NLR, LLR, PLR and SIRI did not. mGPS was associated with more advanced stages (p < 0.001) and weight loss (p = 0.002). mGPS poses a feasible prognostic tool in patients with locally advanced gastroesophageal cancer.
Identifiants
pubmed: 37750955
doi: 10.1007/s00432-023-05424-4
pii: 10.1007/s00432-023-05424-4
pmc: PMC10657318
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17081-17091Informations de copyright
© 2023. The Author(s).
Références
Diagnostics (Basel). 2022 Feb 25;12(3):
pubmed: 35328146
Curr Oncol. 2022 Nov 27;29(12):9242-9254
pubmed: 36547138
Clin Cancer Res. 2013 Oct 1;19(19):5456-64
pubmed: 23938289
Can J Gastroenterol Hepatol. 2022 Jun 13;2022:3953004
pubmed: 35734015
Acta Gastroenterol Belg. 2020 Apr-Jun;83(2):255-263
pubmed: 32603044
Gastric Cancer. 2017 Jan;20(1):126-135
pubmed: 26874951
Cancers (Basel). 2021 Sep 22;13(19):
pubmed: 34638228
Int J Mol Sci. 2022 Mar 26;23(7):
pubmed: 35408994
Front Oncol. 2022 Mar 07;12:831207
pubmed: 35321436
Future Oncol. 2018 Oct;14(24):2493-2505
pubmed: 29969285
Ann Surg. 2021 Mar 1;273(3):532-541
pubmed: 31425286
Gastric Cancer. 2022 Sep;25(5):906-915
pubmed: 35763187
Br J Cancer. 2011 Feb 15;104(4):726-34
pubmed: 21266974
Oncology. 2016;90(6):321-6
pubmed: 27225990
Front Oncol. 2021 Feb 25;11:577043
pubmed: 33718137
ESMO Open. 2022 Apr;7(2):100445
pubmed: 35398717
ESMO Open. 2020 Nov;5(6):e000863
pubmed: 33184096
Br J Cancer. 2012 Jul 10;107(2):275-9
pubmed: 22713657
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Br J Cancer. 2021 Mar;124(7):1294-1300
pubmed: 33473170
Cancers (Basel). 2022 Apr 14;14(8):
pubmed: 35454903
Eur J Surg Oncol. 2018 May;44(5):607-612
pubmed: 29478743
Ann Oncol. 2022 Oct;33(10):992-1004
pubmed: 35914638
J Gastroenterol. 2014 Jun;49(6):1040-6
pubmed: 23821018
Transl Gastroenterol Hepatol. 2020 Oct 05;5:55
pubmed: 33073050
N Engl J Med. 2022 Jun 16;386(24):2261-2272
pubmed: 35657320
Sci Rep. 2023 Apr 28;13(1):6952
pubmed: 37117200
Ann Oncol. 2022 Jul;33(7):685-692
pubmed: 35395383
Nature. 2022 Mar;603(7903):942-948
pubmed: 35322232
Cancers (Basel). 2021 Dec 31;14(1):
pubmed: 35008350
Clin Chim Acta. 2020 Dec;511:81-89
pubmed: 33002476
PLoS One. 2020 Jul 27;15(7):e0236445
pubmed: 32716955
BMC Surg. 2023 Jan 12;23(1):8
pubmed: 36635689
Cancer Biomark. 2015;15(6):899-907
pubmed: 26444485
Gastric Cancer. 2017 Jul;20(4):602-611
pubmed: 27665104
Cancer Med. 2023 Feb;12(4):4206-4217
pubmed: 36214475
J Clin Epidemiol. 2001 Apr;54(4):343-9
pubmed: 11297884
Front Immunol. 2021 Dec 07;12:759250
pubmed: 34950137
Ann Oncol. 2022 Oct;33(10):1005-1020
pubmed: 35914639
J Gastrointest Oncol. 2019 Jun;10(3):400-406
pubmed: 31183188
Future Oncol. 2022 Jul;18(21):2623-2634
pubmed: 35616013
J Clin Med. 2022 Sep 09;11(18):
pubmed: 36142965
Surg Oncol. 2022 Aug;43:101791
pubmed: 35716547